Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLAGYL ER vs METRONIDAZOLE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.
Upon anaerobic reduction of the nitro group, forms toxic intermediates that damage bacterial DNA and inhibit nucleic acid synthesis.
Treatment of bacterial vaginosis (FDA-approved),Off-label: Clostridium difficile infection, anaerobic infections, trichomoniasis, amebiasis, giardiasis, rosacea, periodontal disease, Helicobacter pylori eradication
Trichomoniasis,Bacterial vaginosis,Anaerobic infections (intra-abdominal, gynecologic, skin and skin structure),Pelvic inflammatory disease (in combination with other antibiotics),Pseudomembranous colitis (Clostridioides difficile infection),Rosacea (topical),Helicobacter pylori eradication (in combination therapy),Crohn's disease (perianal fistulas, off-label),Giardiasis (off-label)
750 mg orally once daily for 10 days for bacterial vaginosis.
Intravenous: 500 mg every 6 hours or 500 mg every 8 hours. Typical adult dose: 500 mg IV every 6 hours.
Terminal elimination half-life: 6-8 hours (increased to 10-12 hours with hepatic impairment; unchanged in renal impairment).
7-8 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment.
Hepatic metabolism via side-chain oxidation and glucuronidation; metabolites are 5-nitroimidazoles and hydroxy metabolites; CYP450 enzymes (CYP2A6, CYP3A4, CYP2B6) partially involved.
Hepatic metabolism via oxidation (CYP450 enzymes) and glucuronidation; major metabolites include hydroxy-metronidazole (active).
Renal: 60-80% (metabolites and unchanged drug). Fecal: 6-15%. Minimal biliary.
Renal 60-80% as unchanged drug and metabolites; fecal 6-15%; biliary minor.
<20% (albumin).
<20% bound to plasma proteins.
0.5-0.8 L/kg; indicates extensive tissue distribution including CNS.
0.6-1.1 L/kg; wide distribution including CNS, abscesses, and bone.
Oral: 80-95% (extended-release formulation).
Oral: 80-100%; IV: 100%.
No adjustment necessary for GFR >10 m L/min; for GFR <10 m L/min, consider using immediate-release metronidazole instead of FLAGYL ER due to lack of data in severe renal impairment.
No dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, administer 500 mg IV every 12 hours. Metronidazole and metabolites are removed by hemodialysis; administer after dialysis session.
Child-Pugh Class A/B: no adjustment necessary. Child-Pugh Class C: reduce dose to 375 mg orally once daily (50% of usual dose).
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: Reduce dose by 50% and consider extended interval (e.g., 500 mg IV every 8-12 hours). Child-Pugh Class C: Reduce dose by 75% (e.g., 250 mg IV every 12 hours or 500 mg IV every 24 hours).
Safety and efficacy not established for FLAGYL ER in pediatric patients. Use immediate-release metronidazole for pediatric dosing.
Neonates: 15 mg/kg IV loading dose, then 7.5 mg/kg IV every 12-24 hours depending on gestational age. Infants and children: 10 mg/kg IV every 6-8 hours; maximum 4 g/day. For serious infections, up to 15 mg/kg IV every 6 hours.
No specific dose adjustment recommended based on age alone; use caution due to potential for decreased renal function and monitor for adverse effects.
No specific dose adjustment; monitor renal function due to age-related decline. For Cr Cl <10 m L/min, adjust per renal guidelines. Caution with prolonged use due to potential neurotoxicity.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Avoid chronic use. Reserved for anaerobic and protozoal infections.
Carcinogenicity in animal studies; reserved for indications where other therapies have been inadequate.
Peripheral neuropathy (risk with prolonged use), CNS effects (seizures, encephalopathy), disulfiram-like reaction with alcohol, sodium overload (each tablet contains 84 mg sodium), hepatic impairment may increase risk of toxicity, renal impairment (dose adjustment not typically required but monitor), superinfection including C. difficile diarrhea.
Carcinogenicity (animal data), seizures and peripheral neuropathy (especially with high doses or prolonged use), disulfiram-like reaction with alcohol, methemoglobinemia, QT prolongation, hepatic impairment (dose adjustment recommended), pregnancy (avoid in first trimester unless essential), lactation (use caution).
Hypersensitivity to metronidazole or other nitroimidazoles; concurrent use of disulfiram (psychotic reactions); caution in pregnancy (first trimester only if clearly needed; crosses placenta); breastfeeding (use caution due to potential carcinogenicity).
Hypersensitivity to metronidazole or nitroimidazole derivatives, first trimester of pregnancy (unless alternative therapies unavailable), concomitant use with disulfiram (within 2 weeks), concomitant use with alcohol or propylene glycol-containing products.
Avoid alcohol and any products containing alcohol (e.g., mouthwash, cough syrups, cooking wine) during therapy and for 48 hours after last dose. No specific food restrictions otherwise.
Alcohol must be strictly avoided during therapy and for at least 48 hours after completion to prevent a disulfiram-like reaction (nausea, vomiting, flushing, headache). No other significant food interactions; however, taking with meals can reduce gastrointestinal upset.
Trimester 1: Crosses placenta; contraindicated in first trimester due to risk of carcinogenicity in animal studies and potential teratogenicity; use only for life-threatening infections. Trimester 2 and 3: Use with caution; associated with increased risk of cleft lip/palate in some studies; avoid if possible.
Metronidazole crosses the placenta. First trimester: studies show no consistent increased risk of major malformations, but some reports suggest possible association with cleft lip/palate; avoid unless essential. Second and third trimesters: generally considered safe for short-term use; no evidence of significant fetal harm.
Excreted in breast milk; M/P ratio ~0.9; American Academy of Pediatrics considers compatible with breastfeeding, but advise caution; monitor infant for diarrhea or oral thrush.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9; infant exposure is about 10-20% of maternal dose. Avoid high-dose or prolonged use; after a single 2 g dose, withhold breastfeeding for 12-24 hours; for standard doses, caution advised, though AAP considers compatible.
No specific dose adjustments recommended based on pregnancy pharmacokinetics; however, due to increased GFR in pregnancy, consider monitoring therapeutic levels for severe infections.
No routine dose adjustment required in pregnancy; pharmacokinetic changes (increased volume of distribution, decreased plasma protein binding) may slightly alter drug levels but clinical significance not established; use lowest effective dose for shortest duration.
FLAGYL ER (metronidazole extended-release) is indicated for bacterial vaginosis. Avoid alcohol during therapy and for 48 hours after completion due to disulfiram-like reaction. Monitor for peripheral neuropathy; discontinue if signs occur. Use with caution in hepatic impairment; dose adjustment may be needed. May cause metallic taste.
Metronidazole hydrochloride is metabolized hepatically and excreted renally; dosing adjustment needed for severe hepatic impairment (Child-Pugh C). Avoid alcohol during therapy and for 48 hours after completion due to disulfiram-like reaction. Monitor for peripheral neuropathy with prolonged use; discontinue if signs appear. IV formulation contains sodium; caution in heart failure or hypertension. Drug interactions: warfarin (enhanced anticoagulation), lithium (increased toxicity), phenytoin (increased phenytoin levels), and cimetidine (decreased clearance).
Take this medication exactly as prescribed; do not crush or chew the extended-release tablets.,Avoid all alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, and flushing.,Complete the full course even if symptoms improve to ensure infection is fully treated.,Report any numbness, tingling, or pain in hands or feet to your doctor immediately.,Inform your healthcare provider if you have liver disease, a history of blood disorders, or are pregnant or breastfeeding.
Finish the entire course of medication even if you feel better.,Avoid alcohol and any alcohol-containing products (e.g., mouthwash, cough syrup) during treatment and for 48 hours after the last dose; serious nausea, vomiting, and headache may occur.,Take with food to reduce stomach upset.,Metronidazole may cause a metallic taste; this is temporary.,Contact your healthcare provider if you experience numbness or tingling in your hands or feet.,This medication can cause dizziness; avoid driving or operating machinery if affected.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Report any signs of new infection, such as fever or chills.
No interactions on record
"Metronidazole is a known inhibitor of CYP3A4, the primary enzyme responsible for metabolizing Osimertinib. Coadministration increases Osimertinib AUC by approximately 30-60%, leading to elevated plasma concentrations that may potentiate adverse effects such as QTc prolongation, interstitial lung disease, and diarrhea. Clinicians should monitor for signs of Osimertinib toxicity and consider dose reduction if concurrent use is unavoidable."
"Metronidazole inhibits CYP3A4, the primary enzyme responsible for the metabolism of ergotamine. Co-administration can lead to significantly elevated ergotamine plasma concentrations, increasing the risk of ergotism—a serious condition characterized by severe vasoconstriction, ischemia, and potential gangrene of the extremities. Patients may present with symptoms such as cold, painful extremities, muscle pain, and paresthesias, requiring immediate intervention."
"Levofloxacin and metronidazole both prolong the QT interval, and their concurrent use can lead to additive effects on cardiac repolarization. This increases the risk of torsade de pointes, a potentially fatal ventricular arrhythmia. Patients with pre-existing QT prolongation, electrolyte disturbances, or bradycardia are at higher risk."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLAGYL ER vs METRONIDAZOLE HYDROCHLORIDE, answered by our medical review team.
FLAGYL ER is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.. METRONIDAZOLE HYDROCHLORIDE is a Nitroimidazole Antibiotic that works by Upon anaerobic reduction of the nitro group, forms toxic intermediates that damage bacterial DNA and inhibit nucleic acid synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLAGYL ER and METRONIDAZOLE HYDROCHLORIDE depend on the specific clinical indication. These are both Nitroimidazole Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLAGYL ER is: 750 mg orally once daily for 10 days for bacterial vaginosis.. The standard adult dose of METRONIDAZOLE HYDROCHLORIDE is: Intravenous: 500 mg every 6 hours or 500 mg every 8 hours. Typical adult dose: 500 mg IV every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLAGYL ER and METRONIDAZOLE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLAGYL ER is classified as Category C. Trimester 1: Crosses placenta; contraindicated in first trimester due to risk of carcinogenicity in animal studies and potential teratogenicity; use only for life-threatening infec. METRONIDAZOLE HYDROCHLORIDE is classified as Category A/B. Metronidazole crosses the placenta. First trimester: studies show no consistent increased risk of major malformations, but some reports suggest possible association with cleft lip/. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.